Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.

Myc family proteins promote cancer by inducing widespread changes in gene expression. Their rapid turnover by the ubiquitin-proteasome pathway is regulated through phosphorylation of Myc Box I and ubiquitination by the E3 ubiquitin ligase SCFFbxW7 However, N-Myc protein (the product of the MYCN oncogene) is stabilized in neuroblastoma by the ...
protein kinase Aurora-A in a manner that is sensitive to certain Aurora-A-selective inhibitors. Here we identify a direct interaction between the catalytic domain of Aurora-A and a site flanking Myc Box I that also binds SCFFbxW7 We determined the crystal structure of the complex between Aurora-A and this region of N-Myc to 1.72-A resolution. The structure indicates that the conformation of Aurora-A induced by compounds such as alisertib and CD532 is not compatible with the binding of N-Myc, explaining the activity of these compounds in neuroblastoma cells and providing a rational basis for the design of cancer therapeutics optimized for destabilization of the complex. We also propose a model for the stabilization mechanism in which binding to Aurora-A alters how N-Myc interacts with SCFFbxW7 to disfavor the generation of Lys48-linked polyubiquitin chains.
Mesh Terms:
Aurora Kinase A, Azepines, Binding Sites, Catalytic Domain, Crystallography, X-Ray, Humans, N-Myc Proto-Oncogene Protein, Neoplasms, Phenylurea Compounds, Phosphorylation, Polyubiquitin, Protein Binding, Protein Kinase Inhibitors, Pyrimidines, SKP Cullin F-Box Protein Ligases
Proc. Natl. Acad. Sci. U.S.A.
Date: Dec. 29, 2015
Download Curated Data For This Publication
211647
Switch View:
  • Interactions 4